Treating pulmonary conditions
a pulmonary condition and treatment method technology, applied in the field of treating pulmonary conditions, can solve the problems of oral steroids, high variability in the therapeutic efficacy of cysteinyl-leukotriene receptor antagonist and cromolyn, and inability to control 5-10% of asthmatics, so as to achieve effective and safe treatment of pulmonary conditions
Inactive Publication Date: 2015-12-17
NUSIRT SCI
View PDF1 Cites 2 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
The present invention provides a low-cost therapy that can safely and effectively treat pulmonary conditions. This is an improvement over existing therapies that may be more expensive or have potential side effects.
Problems solved by technology
However, the therapeutic efficacies of cysteinyl-leukotriene receptor antagonist and cromolyn are highly variable and may be limited to certain subgroup of patients.
In addition, 5-10% of the asthmatics are not well-controlled by current drug treatment and they require oral steroids during exacerbation.
Oral steroid usage is commonly associated with a diversity of adverse effects, most notably increases in appetite, stomach ulcers, difficulty sleeping (insomnia), changes in mood and behavior, flushing (redness) of the face, and short-term weight gain due to increased water retention.
While these agents can ameliorate certain symptoms to some degree, they are not effective to halt progression of COPD.
However, theophylline has a number of side effects.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
example 1
Effects of Leucine, Theophylline, Theobromine and Resveratrol on Indicators of Pulmonary Conditions
[0173]Techniques
[0174]Cell Culture:
[0175]Mouse primary lung endothelial cells (MLEC) were obtained from Cell Biologics (Chicago, Ill.). Cells were grown to confluence in T75 culture flasks precoated with 0.2% gelatin. Cells were grown in Dulbecco's modified eagle's medium (DMEM) containing a growth factor supplement (Cell Biologics # M1 166) which included 5% fetal bovine serum (FBS), heparin, EGF, hydrocortisone, L-glutamine and antibiotics at 37° C. in 5% CO2.
[0176]Adipocyte Conditioned Media Experiments:
[0177]3T3L1 adipocytes (passage 11 to 13) were grown and differentiated on 6-well plates and treated for 48 h with the treatments indicated in “Results”. Media was then collected and pooled together for each treatment group. Pooled media was then used to treat confluent MLEC for 24 h in lieu of direct treatments. The MLEC media from each cell replicate was collected, aliquoted and st...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
| Property | Measurement | Unit |
|---|---|---|
| time | aaaaa | aaaaa |
| time | aaaaa | aaaaa |
| time | aaaaa | aaaaa |
Login to View More
Abstract
Compositions, methods, and kits useful for treating pulmonary conditions are provided herein. Such compositions can contain synergizing amounts of a non-specific phosphodiesterase inhibitor, such as a methylxanthine, in combination with leucine and / or a leucine metabolite, and resveratrol.
Description
CROSS-REFERENCE[0001]This application claims benefit of priority to U.S. Provisional Application No. 61 / 752,909, filed Jan. 15, 2013, which is incorporated herein by reference in its entirety for all purposes.BACKGROUND OF THE INVENTION[0002]Pulmonary diseases or conditions span a range of lung-related diseases, including asthma and chronic obstructive pulmonary disease (COPD), which affect millions of people throughout the world.[0003]For example, over 300 million people worldwide suffering from asthma. It is predicted that the prevalence will increase to about 400 million in the next decade. Asthma is a chronic airway disorder identified by recurrent wheeze and intermittent air flow limitation. It is characterized by airway inflammation, mucus hypersecretion, and airway hyperresponsiveness (AHR). Studies have shown that these clinical manifestations are, at least in part, inflammatory responses mediated by T-helper type 2 (Th2) cells together with mast cells, B cells and eosinophi...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/198A61K31/05A61K31/522
CPCA61K31/198A61K31/05A61K31/522A61K31/19A61P11/00A61P11/06A61K2300/00
Inventor ZEMEL, MICHAELBRUCKBAUER, ANTJEBAGGETT, BROOKE
Owner NUSIRT SCI